Form 4: Guardant Health Exec Sells Shares

Chris Freeman, Chief Commercial Officer at Guardant Health, Inc., reported the sale of 24,406 shares of common stock on May 22, 2026.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, Inc., sold 24,406 shares of common stock on May 22, 2026.
• The sale was executed at a weighted average price of $32.86 per share.
• Following the transaction, Freeman beneficially owns 60,034 shares of common stock.
• The filing also notes a stock option award granted on June 9, 2023, with a portion vesting on June 9, 2024, and the remainder vesting monthly over the subsequent two years.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, although the context of stock options and potential personal financial planning could mitigate concerns.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider selling, particularly by C-suite executives, can sometimes signal a lack of confidence in future stock performance, although it can also be for personal financial planning.

Stakeholder Impact

• Shareholders may view the sale of shares by a Chief Commercial Officer with concern, potentially impacting short-term stock sentiment.

Key Dates

Recommendation

The sale of shares by a key executive warrants attention, but without further context on the reasons for the sale or the company's overall financial health, a 'hold' recommendation is prudent. The existence of stock options and their vesting schedule suggests ongoing executive compensation and potential future share ownership.

Keywords

Guardant Health, Form 4, Insider Trading, Stock Sale, Chris Freeman, Common Stock, Stock Options